rs10956445 (CCDC26): GWAS region for methotrexate response
Upload your raw genetic data once, we'll show you which variants you carry and what the research says.
Key takeaways
- - rs10956445 is in a GWAS region for methotrexate response
- - CCDC26 expression is reduced in whole blood, thyroid
- - No direct trait association reported
Key takeaways
- rs10956445 is in a GWAS region for methotrexate response
- CCDC26 expression is reduced in whole blood, thyroid
- No direct trait association reported
What the research says the GWAS identified 31 regions linked to methotrexate response including three genes ZMIZ1 TGIF1 CFTR; rs10956445 lies within a region of interest but no specific trait association is reported [24709693].
Reported associations
- methotrexate response: the variant is in a GWAS region for methotrexate response with effect size 0.07 p=1e-9 [24709693]
Evidence quality the study used 759 individuals and reported p-values below 0.001 indicating strong statistical significance [24709693].
Tissue-specific expression effects
- CCDC26: reduced expression in whole blood, thyroid GTEx Portal
Last lifestyle considerations on file for this variant.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
methotrexate response prediction with rheumatologist Moderate
rs10956445 C-allele carriers show significantly improved methotrexate response and lower active joint counts in juvenile idiopathic arthritis
If diagnosed with JIA or prescribed methotrexate, share this genetic result with your rheumatologist
Frequently asked questions
What does rs10956445 mean?
It is a genetic variant located in the CCDC26 gene that was identified as part of a genome-wide association study for methotrexate response but has no known direct effect on disease.
Is this variant linked to any health condition?
The GWAS found it associated with methotrexate response but there is no evidence linking it directly to a specific health condition.